When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

Adma Biologics (ADMA) ended the recent trading session at $6.27, demonstrating a +1.13% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.88%. On the other hand, the Dow registered a gain of 0.56%, and the technology-centric Nasdaq decreased by 2.05%.The the stock of infectious disease drug developer has risen by 0.16% in the past month, leading the Medical sector's loss of 6.4% and the S&P 500's loss of 2.57%.The upcoming earnings release of Ad ...

In the latest trading session, Adma Biologics (ADMA) closed at $6.04, marking a -1.95% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.58%. On the other hand, the Dow registered a loss of 0.12%, and the technology-centric Nasdaq decreased by 1.15%.Prior to today's trading, shares of the infectious disease drug developer had lost 0.48% over the past month. This has was narrower than the Medical sector's loss of 6.07% and the S&P 500's loss of 1.09% in that time.The ...

U.S. stock markets maintained their northbound journey in the first quarter of 2024 after an impressive 2023. In first-quarter 2024, the S&P 500 rallied 10.2%, marking its best first-quarter performance since 2019. The Dow surged 5.6%, reflecting its strongest first-quarter performance since 2021. The tech-heavy Nasdaq Composite appreciated 9.1% in the same quarter.However, volatility returned to Wall Street in the first week of April. The Dow slid 2.3%, posting its worst weekly performance in 2024. The S&P ...

ADMA Biologics, Inc. (ADMA) markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company markets Bivigam (to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).ADMA Biologics’ top line currently comprises sales of these three FDA-approved products. The company’s commercial specialty biologics product portfolio is witn ...

Adma Biologics (ADMA) closed the latest trading day at $6.54, indicating a -0.91% change from the previous session's end. The stock trailed the S&P 500, which registered a daily loss of 0.2%. Elsewhere, the Dow lost 0.6%, while the tech-heavy Nasdaq added 0.11%.The the stock of infectious disease drug developer has risen by 19.57% in the past month, leading the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32%.The investment community will be closely monitoring the performance of Adma Biologics ...

Adma Biologics (ADMA) closed at $6.29 in the latest trading session, marking a +1.62% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.14%. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, added 0.17%.The infectious disease drug developer's shares have seen an increase of 17.68% over the last month, surpassing the Medical sector's gain of 0.88% and the S&P 500's gain of 5.34%.Analysts and investors alike will be keeping a close eye on the performance ...

U.S. stock markets have been maintaining their northbound journey in the first quarter of 2024 after an impressive 2023. Year to date, the three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — have rallied 4.8%, 10.2% and 10.9%, respectively.On Mar 20, after its FOMC meeting, the Fed kept the benchmark lending rate constant in the range of 5.25-5.5%. However, the Fed’s latest “dot-plot” (a closely watched matrix of anonymous projections from the 19 officials who comprise the FOMC) show ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Adma Biologics (ADMA) closed the last trading session at $5.99, gaining 13.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8 indicates a 33.6% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $1.63. While the lowest estimate of $6 indicates a 0.2% increase from the current price level, the most optimistic analyst expects th ...